A guest of the Oncology Academy for patients is ELENA LUBENNIKOVA, PhD, Senior Researcher, Chemotherapy Department No. 1, N.N. Blokhin National Medical Research Center of Oncology. The broadcast was supported by Novartis Pharma LLC. Contents: 00:00 Introduction 02:14 Luminal HER2-negative and metastatic breast cancer – what does this mean? 07:46 About the features of luminal cancer therapy 19:09 Endocrine therapy and CDK inhibitors do not provide immediate results? 21:45 Use CDK inhibitors or chemotherapy in treatment – ​​how do doctors make a decision? 23:39 At what price do we prolong life? About the choice of the necessary therapy 28:01 Is artificial menopause difficult to tolerate? 29:09 How to help your body during artificial menopause? 35:31 Does hormonal ("antihormonal") therapy affect weight gain? 37:09 "If Abemaciclib is not available, is it possible to replace it with another CDK inhibitor or a specific drug?" 40:22 CDK inhibitors: if treatment is delayed or the drug dose is reduced due to changes in blood counts - does this affect the effectiveness of therapy? 43:30 About the doctors of the Oncology Center, their experience and the doctor's intuition 45:30 A few words about our projects: Oncology Academy for patients and "Children's Environment" 46:28 Should we despair if doctors say they will make the disease chronic? 51:33 Does rebiopsy make sense in luminal HER2-negative metastatic cancer? 54:25 About new HER2 statuses of tumors and promising drugs 57:11 "What new drugs are expected?" 58:55 "Should I remove my ovaries? I've been on Zoladex and aromatase inhibitors for 4 years" 1:00:44 "In what cases is local control used in metastatic breast cancer?" 1:02:21 Do all our patients go through a consultation of doctors? 1:03:12 Let's return to the question "Should I remove my ovaries? I've been on Zoladex and aromatase inhibitors for 4 years" 1:05:04 "How effective is Fulvestrant as a monotherapy for liver metastases? Is it possible to add Ribociclib if it progresses?" 1:06:04 "At 47 years old, with stage 2B luminal cancer with 65% CI, G3, which hormone therapy is preferable? Ovariectomy performed" 1:06:44 On how to get an appointment at the Oncology Center - in particular, to see a specific doctor 1:11:19 Telemedicine capabilities 1:11:37 "When will Kapivasertib and Elasestrant be included in clinical guidelines?" 1:13:07 "At an early stage, is it necessary to connect ciclib to inhibitors? Or is this only for metastatic breast cancer?" 1:15:42 "Should zoledronic acid be administered after starting to take inhibitors after 6 months or based on the results of densitometry in the presence of osteoporosis?" 1:17:42 "I am taking Capecitabine, it is currently not available under the compulsory medical insurance, what should I do?" #directairblokhin every Thursday at 12:00 with you on the official page of the N.N. Sechenov National Medical Research Center of Oncology. Blokhin on VK: https://vk.com/publicn.n.blokhincrc Recordings of all broadcasts can be found on the official channel of the N.N. Blokhin National Medical Research Center of Oncology on YouTube: / @roncofficial Single contact center of the N.N. Blokhin National Medical Research Center: +7 499 444 24 24 #livebroadcastblokhin #oncologyacademyforpatients #oncologycenteronkashirka #blokhin